 THE WOODLANDS, Texas, Dec. 11, 2020 GLOBE NEWSWIRE -- Lexicon Pharmaceuticals, Inc. Nasdaq: LXRX, announced today that it has received Fast Track designation from the U.S. Food and Drug Administration FDA for the development of LX9211 in diabetic peripheral neuropathic pain. 